GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (NSE:AUROPHARMA) » Definitions » Cash Conversion Cycle

Aurobindo Pharma (NSE:AUROPHARMA) Cash Conversion Cycle : 218.28 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aurobindo Pharma Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Aurobindo Pharma's Days Sales Outstanding for the three months ended in Mar. 2024 was 58.67.
Aurobindo Pharma's Days Inventory for the three months ended in Mar. 2024 was 292.4.
Aurobindo Pharma's Days Payable for the three months ended in Mar. 2024 was 132.79.
Therefore, Aurobindo Pharma's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 218.28.


Aurobindo Pharma Cash Conversion Cycle Historical Data

The historical data trend for Aurobindo Pharma's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma Cash Conversion Cycle Chart

Aurobindo Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 235.77 253.41 245.72 216.23 203.74

Aurobindo Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 208.34 194.23 193.88 196.57 218.28

Competitive Comparison of Aurobindo Pharma's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's Cash Conversion Cycle falls into.



Aurobindo Pharma Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Aurobindo Pharma's Cash Conversion Cycle for the fiscal year that ended in Mar. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=59.02+265.28-120.56
=203.74

Aurobindo Pharma's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=58.67+292.4-132.79
=218.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aurobindo Pharma  (NSE:AUROPHARMA) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Aurobindo Pharma Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurobindo Pharma (NSE:AUROPHARMA) Business Description

Traded in Other Exchanges
Address
Plot No. 1, Survey No. 83/1, Galaxy, Floors: 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500 032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. The company's product portfolio spans a variety of therapeutic areas. The vast majority of the company's sales are generated in the United States, followed by Europe. Most of Aurobindo's sales are derived from its formulations business, with the rest stemming from its active pharmaceutical ingredient operations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Aurobindo Pharma (NSE:AUROPHARMA) Headlines

No Headlines